Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14798040 | 0.95 | — | — | |
| SCHEMBL10939811 | 0.84 | GABRR1 (0.30) | GABRR1 | |
| SCHEMBL6697349 | 0.81 | GABRR1 (0.45) | GABRR1 | |
| SCHEMBL4705539 | 0.81 | GABRR1 (0.45) | GABRR1 | |
| SCHEMBL285517 | 0.80 | — | — | |
| SCHEMBL18920952 | 0.78 | NFKB1 (0.48) | GABRR1 | |
| SCHEMBL1640046 | 0.78 | — | — | |
| SCHEMBL16585569 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL2708490 | 0.74 | BLM (0.43) | GABRR1 | |
| SCHEMBL28907284 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116171282-A | Soluble NPY2 receptor agonists | 勃林格殷格翰国际有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-2474553-B1 | Compounds for diagnosing apoptosis | GUERBET SA (FR) | 2015-01-21 | — | — | EP | disclosed |
| EP-2474553-A2 | Compounds for diagnosing apoptosis | GUERBET (FR) | 2012-07-11 | — | — | EP | disclosed |
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | GUERBET (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2137208-A2 | COMPOUNDS FOR DIAGNOSING APOPTOSIS | GUERBET (FR) | 2009-12-30 | — | — | EP | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| WO-2008125420-A2 | COMPOUNDS FOR DIAGNOSING APOPTOSIS | GUERBET (FR) | 2008-10-23 | — | — | WO | disclosed |
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| EP-1940823-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| EP-1737840-B1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-03 | — | — | US | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042668-A1 | DERIVATIVES OF 1-AMINO-ISOQUINOLINE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS IN THE TREATMENT OF A DYSFUNCTION ASSOCIATED WITH MCH RECEPTOR 1 | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042669-A2 | DERIVATIVES OF 4-AMINO-QUINAZOLINE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFIS-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| EP-1737840-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005103033-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143250-A1 | COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS | TPX2, VIP, BAX | GABRR1 3214/4885 |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, GOT2 | GABRR1 1337/4885 |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | GABRR1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.